Summary of Use during Lactation

No information is available on the clinical use of calaspargase pegol during breastfeeding. Because calaspargase is a large protein molecule with a molecular weight of about 140,000 Da, the amount in milk is likely to be very low and it is probably partially destroyed in the infant's gastrointestinal tract and poorly absorbed by the infant. Polyethylene glycol is not excreted into breastmilk.[1] However, the manufacturer recommends that the drug not be used during breastfeeding and for 3 months after the last dose.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Clowse ME, Förger F, Hwang C, et al. Minimal to no transfer of certolizumab pegol into breast milk: Results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study. Ann Rheum Dis. 2017;76:1890–6. [PMC free article: PMC5705850] [PubMed: 28814432]

Substance Name

Calaspargase Pegol

CAS Registry Number

130167-69-0

Drug Class

Breast Feeding

Lactation

Antineoplastic Agents

Enzymes